BPC-157 and the FDA: What the July 2026 Hearing Actually Means

What the Committee Actually Voted

The votes were close, and they went against the FDA's own reviewers. FDA staff briefing materials had recommended against adding any of the seven peptides, concluding that the available human studies — five of them for BPC-157 — were too small and too short to establish safety or effectiveness.⁴ The committee disagreed, narrowly.

Press reports of the meeting put the BPC-157 vote at 8 in favor, 6 against, with 1 abstention, the same split as KPV and TB-500 on day one.⁴ FDA has not published vote tallies on its own meeting page, so treat the exact numbers as reported rather than official; what is not in dispute is that the recommendation was favorable and that it was not unanimous.¹

Six peptides were recommended: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide, also called delta sleep-inducing peptide, was the one the committee declined to recommend.⁴

What Happens Next, and How Long It Takes

Adding a substance to the 503A Bulks List requires formal notice-and-comment rulemaking: FDA publishes a proposed rule, takes public comment, reviews the record, and then issues a final rule. FDA is not obliged to follow the committee — it can accept, modify, or decline the recommendation, and it could hold to its original position that none of the seven should be added. There is no statutory deadline, and in at least one prior case the final rule came more than two years after the proposed rule.⁵

As of November 1, 2026, I found no FDA proposed rule on these peptides in the Federal Register, and the policy HHS published on October 30 applies only to peptides not on the bulks list codified at 21 CFR 216.23(a), which as of its publication lists none of the six.⁶¹⁰ Until a rule is finalized, the favorable vote confers nothing on its own: it does not approve BPC-157 and does not list it. Any pharmacy or clinic marketing the vote as FDA approval is misrepresenting it.

What Changed on October 30: HHS's Draft Enforcement Discretion Policy

On October 30, 2026, the Department of Health and Human Services published a notice of availability in the Federal Register (91 FR 68526; Docket HHS-OASH-2026-0496) for a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.”⁹ It carries the same RIN, 0910-ZD94, as the “Interim Access Policy” that an earlier version of this post reported as pending at the White House Office of Information and Regulatory Affairs.⁷

The policy says HHS “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician” that compounds with a peptide on its Appendix A list. Appendix A names six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, the same six the committee recommended.¹⁰ The policy applies while the 503A bulks list is developed through rulemaking, and the notice says FDA's future rulemakings “may propose adding some or all of these peptides.”⁹ HHS describes the aim as steering patients away from research-use-only peptides from foreign manufacturers toward a more controlled alternative.¹⁰

The protection is conditional. All ten of these must be present:¹⁰

1. The peptide is on Appendix A.
2. Its identity and route of administration match the descriptions in Appendix B. For BPC-157, Appendix B limits coverage to BPC-157 acetate in subcutaneous, intramuscular, oral and topical dosage forms compounded from API with a qualifying certificate of analysis; other forms and routes are not covered.
3. The bulk substance comes from a facility registered under section 510 and has a valid certificate of analysis.
4. The original manufacturer, not a repacker or distributor, is registered, is in CGMP compliance, and is listed on the certificate of analysis.
5. The compounder reports serious adverse events and product quality issues to FDA (MedWatch) and to the relevant States, and reports the products compounded (active ingredient and strength, original manufacturer and facility identifier, dosage form and route).
6. The label states: “This is a compounded drug product. Not for resale.”
7. The product contains only a single Appendix A peptide as its active ingredient.
8. For oral products, the compounder documents adequate oral bioavailability.
9. The only co-packaged delivery device is an FDA 510(k)-cleared syringe.
10. The product is compounded in compliance with all other FD&C Act requirements, including not being prepared under insanitary conditions and the patient-specific prescription requirement of section 503A.

What it is not: the notice calls it a draft; it “does not establish any rights for any person and is not binding on HHS or the public”; and HHS may revisit it, for example if a safety signal or product quality issue arises.⁹ It does not approve BPC-157, does not add it to the bulks list, and says nothing that turns research-chemical products into legal ones. As I read it, it speaks to federal enforcement only. The notice set a comment deadline of two weeks after publication, which works out to November 13, 2026, on Regulations.gov; the notice also says to check HHS's website for the most current version.⁹ For the pharmacist's view of how this fits with 503A and 503B, see Peptide Compounding Law for Pharmacists.

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic peptide, a 15-amino-acid fragment derived from a protective protein found in human gastric juice.² It was first characterized in the early 1990s, and decades of preclinical research — almost entirely in animal models — have studied its effects on tissue repair, gut protection, and wound healing.

It is not currently approved by the FDA for any human medical use. It has not completed controlled human clinical trials establishing safety or efficacy. Most of what circulates online about it comes from animal studies, anecdote, and marketing from companies selling it as a "research chemical."

What Was Actually Decided on July 23?

The FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157 (along with KPV, TB-500, and MOTs-C on day one, and three additional peptides on day two) for possible inclusion on the Section 503A Bulk Drug Substances List.¹

Being on that list is one of three statutory routes for a bulk substance in section 503A compounding (the others are a USP or NF monograph and being a component of an FDA-approved drug), and it applies to a drug compounded for an individual patient under a prescription. For BPC-157 specifically, the FDA's own meeting record identifies the use evaluated as ulcerative colitis — not the broad range of uses (tendon injuries, gut health, recovery) that circulate in wellness and fitness spaces.¹ That detail matters: a recommendation tied to ulcerative colitis is not a recommendation for the uses most people are actually buying it for.

What This Hearing Was Not

• It was not an FDA drug approval. BPC-157 did not become an approved medication.
• The committee's vote is advisory, not binding. The FDA can accept, modify, or decline to act on the recommendation.¹
• A favorable vote did not, by itself, change the legal status. Adding a substance to the 503A Bulks List requires a separate, formal FDA rulemaking process — proposed rule, public comment period, then a final rule — that typically takes months to years after a favorable recommendation.⁵
• An unfavorable vote isn't necessarily permanent either; substances can be re-nominated in future review cycles.

In plain terms: July 23 was where the scientific and safety case got argued in public. It was not where BPC-157's legal status changed.

What's the Current Legal Status?

As of November 1, 2026, BPC-157 is not FDA-approved for human use and is not on the 503A Bulks List.⁵¹⁰ Since October 30, a draft HHS policy says HHS does not intend to take enforcement action against pharmacies and physicians who compound it under the conditions above, but that is not approval or listing.⁹ Outside those conditions it still sits in a gray area: it shows up through research-chemical sellers, some compounding pharmacies operating with varying degrees of regulatory scrutiny, and telehealth or wellness clinics — without the safety, purity, and dosing oversight that comes with an FDA-approved drug or a properly regulated compounded prescription.

That gray-market reality is exactly why the hearing mattered. The favorable vote is a step toward a regulated, prescription-based, pharmacist-dispensed pathway with real oversight — but only a step, and the unregulated marketplace is still what exists in the meantime.

Why the Public Docket Matters

FDA opened a public docket (Docket No. FDA-2025-N-6895) for written comment on this hearing, which closed July 22, 2026, the day before the meeting.¹⁸ Advisory committees like PCAC exist specifically to give outside experts — and the public — a documented voice in decisions like this one.³ Comments received by July 9 went to the committee; FDA said comments received after that, through the July 22 close, would still be considered by the agency, while late comments filed after the docket closed would not.⁸ That the process happened in the open, with a public record and a split vote on the record, is worth understanding on its own.

Frequently Asked Questions